{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:56:53Z","timestamp":1777589813067,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ucl.2015.02.001","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T08:45:44Z","timestamp":1425631544000},"page":"159-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel Therapeutic Approaches for Recurrent Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1016","volume":"42","author":[{"given":"Brock E.","family":"Boehm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2015.02.001_bib1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ucl.2015.02.001_bib2","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.5489\/cuaj.1196","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ucl.2015.02.001_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.ucl.2015.02.001_bib4","first-page":"3314","article-title":"Penetration of mitomycin C in human bladder","volume":"53","author":"Wientjes","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2015.02.001_bib5","first-page":"875","article-title":"Electromotive delivery of mitomycin C into human bladder wall","volume":"57","author":"Di Stasi","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2015.02.001_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2015.02.001_bib7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2015.02.001_bib8","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2015.02.001_bib9","first-page":"448","article-title":"A\u00a0phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib10","first-page":"1633","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nm.1928","article-title":"Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells","volume":"15","author":"Jagannath","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ucl.2015.02.001_bib12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1940-6207.CAPR-09-0169","article-title":"Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer","volume":"2","author":"Seager","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.ucl.2015.02.001_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijbiomac.2012.11.026","article-title":"A\u00a0novel injectable temperature-sensitive zinc doped chitosan\/beta-glycerophosphate hydrogel for bone tissue engineering","volume":"54","author":"Niranjan","year":"2013","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.ucl.2015.02.001_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.18632\/oncotarget.852","article-title":"Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression","volume":"4","author":"Delto","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2015.02.001_bib15","first-page":"708","article-title":"Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer","volume":"192","author":"Arends","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2015.02.001_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/iju.12639","article-title":"Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?","volume":"22","author":"Kiss","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A\u00a0pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ucl.2015.02.001_bib19","unstructured":"NIH. vol. 2015. Available at: ClinicalTrials.gov. 2014. Accessed January 3, 2015."},{"key":"10.1016\/j.ucl.2015.02.001_bib20","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.4049\/jimmunol.172.11.7200","article-title":"Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment","volume":"172","author":"Loskog","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ucl.2015.02.001_bib21","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma\u2013the first phase I\/IIa trial","volume":"16","author":"Malmstrom","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2015.02.001_bib22","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/bjc.1995.160","article-title":"Retinoblastoma gene mutations in primary human bladder cancer","volume":"71","author":"Miyamoto","year":"1995","journal-title":"British J Cancer"},{"key":"10.1016\/j.ucl.2015.02.001_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2015.02.001_bib24","first-page":"2391","article-title":"A\u00a0first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cytogfr.2007.06.007","article-title":"Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer","volume":"18","author":"Nagabhushan","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ucl.2015.02.001_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ucl.2015.02.001_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein","volume":"10","author":"Benedict","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.ucl.2015.02.001_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2015.02.001_bib29","first-page":"850","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib30","first-page":"2379","article-title":"Phase I\/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin","volume":"180","author":"Sidi","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib31","first-page":"1697","article-title":"DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer","volume":"191","author":"Gofrit","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib32","first-page":"1633","article-title":"Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder","volume":"166","author":"Morales","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib33","doi-asserted-by":"crossref","first-page":"728930","DOI":"10.1155\/2011\/728930","article-title":"Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancer","volume":"2011","author":"Luo","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.ucl.2015.02.001_bib34","doi-asserted-by":"crossref","first-page":"e94883","DOI":"10.1371\/journal.pone.0094883","article-title":"Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses","volume":"9","author":"Gerard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2015.02.001_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00345-009-0382-4","article-title":"Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer","volume":"27","author":"Hendricksen","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib36","first-page":"1195","article-title":"Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer","volume":"187","author":"Hendricksen","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib37","first-page":"904","article-title":"Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer","volume":"31","author":"Li","year":"2009","journal-title":"Zhonghua zhong liu za zhi"},{"key":"10.1016\/j.ucl.2015.02.001_bib38","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/cncr.10496","article-title":"Randomized study of single early instillation of (2\u201dR)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma","volume":"94","author":"Okamura","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2015.02.001_bib39","first-page":"2805","article-title":"Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study","volume":"126","author":"Li","year":"2013","journal-title":"Chin Med J"},{"key":"10.1016\/j.ucl.2015.02.001_bib40","first-page":"1712","article-title":"A\u00a0phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/aje\/kwj028","article-title":"Hormonal and reproductive factors and the risk of bladder cancer in women","volume":"163","author":"McGrath","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ucl.2015.02.001_bib42","unstructured":"Abstracts of papers presented at the thirtieth annual meeting of the American Society for Cell Biology. San Diego, California. December 9\u201313, 1990. The Journal of Cell Biology 111, 1a-511a (1990)."},{"key":"10.1016\/j.ucl.2015.02.001_bib43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1593\/tlo.13247","article-title":"Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen","volume":"6","author":"George","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ucl.2015.02.001_bib44","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.urolonc.2012.05.007","article-title":"Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in\u00a0vivo","volume":"31","author":"Jinesh","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2015.02.001_bib45","first-page":"2347","article-title":"Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder","volume":"177","author":"Smith","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1442-2042.2010.02503.x","article-title":"Intravesical toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer","volume":"17","author":"Hayashi","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2015.02.001_bib47","first-page":"2077","article-title":"Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer","volume":"189","author":"Falke","year":"2013","journal-title":"J\u00a0Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014315000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014315000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:26:27Z","timestamp":1758806787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014315000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0094014315000087"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2015.02.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapeutic Approaches for Recurrent Nonmuscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2015.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}